Frankfurt
20.08.26 | 08:03
0,102 Euro
+31,27 % +0,024
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | NEXTCELL PHARMA AB: NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong | 1 | Cision News | ||
| 28.05. | NextCell Pharma AB: Interim Report first quarter 2026 | 316 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the first quarter 2026. The report is available on the company's website: www.nextcellpharma.com. NextCells share... ► Artikel lesen | |
| 27.05. | Nextcell Pharma AB: Nextcell Pharma AB (publ) Annual General Meeting 2026 | 305 | GlobeNewswire (Europe) | On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 ("NextCell" or the "Company"), was held. A summary of the resolutions adopted at the Annual General... ► Artikel lesen | |
| 06.05. | FUJIFILM Biosciences and NextCell Launch Global Research-Use Stromal Cell Platform | 3 | Contract Pharma | ||
| 06.05. | NEXTCELL PHARMA AB: NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 4 | Cision News | ||
| 06.05. | FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 510 | Business Wire | Collaboration results in platform to help researchers overcome challenges in MSC research NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product... ► Artikel lesen | |
| 04.05. | NEXTCELL PHARMA AB: NextCell Pharma publishes Annual Report 2024/2024 | 1 | Cision News | ||
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.03. | NEXTCELL PHARMA AB: ProTrans Phase II COVID-19 Trial Accepted for Publication in Cytotherapy | 3 | Cision News | ||
| 03.03. | NEXTCELL PHARMA AB: NextCell Pharma presents historical quarterly figures | 2 | Cision News | ||
| 26.02. | NextCell Pharma AB: NextCell publishes Year-End Report 2024/2025 | 300 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Year-End Report for the extended financial year September 1, 2024 - December 31, 2025. The report is available on the company's... ► Artikel lesen | |
| 03.02. | NextCell Pharma AB: Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes | 207 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with... ► Artikel lesen | |
| 21.01. | NextCell Pharma AB: NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market | 202 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans in adult patients... ► Artikel lesen | |
| 15.01. | NextCell Pharma AB: Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes | 242 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation... ► Artikel lesen | |
| 02.12.25 | NextCell Pharma AB: NextCell initiates collaboration with OptiCell - strengthening its cell-handling operations | 239 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") has entered into a collaboration agreement with OptiCell Solutions AB ("OptiCell") regarding the handling, freezing, storage, and transport of cell products... ► Artikel lesen | |
| 20.11.25 | NextCell Pharma AB: NextCell Pharma appoints Eric Gustafsson as new CFO | 532 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and... ► Artikel lesen | |
| 30.10.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 4 2024/2025 | 231 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 - August 31, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 18.09.25 | NextCell Pharma AB: NextCell Pharma AB announces CFO transition | 253 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company's CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 113,70 | -0,37 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 39,640 | -0,05 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,47 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 38,735 | +3,05 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BIONTECH | 94,80 | -0,16 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| PRAXIS PRECISION MEDICINES | 364,38 | -0,05 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,78 | +0,02 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| NURIX THERAPEUTICS | 27,050 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,760 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,360 | +0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,430 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 35,310 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,02 | +0,17 % | Barclays startet Coverage für Enliven Therapeutics mit "Overweight" und Kursziel von 78 Dollar | ||
| RECURSION PHARMACEUTICALS | 3,335 | -0,15 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| STRUCTURE THERAPEUTICS | 50,52 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
NEXTCELL PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +31,27 % bei einem Aktienkurs von 0,102 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.